Cargando…
Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
Osteosarcoma, the most common primary bone sarcoma, is a genetically complex disease with no widely accepted biomarker to allow stratification of patients for treatment. After a recent report of one osteosarcoma cell line and one tumor exhibiting fibroblastic growth factor receptor 1 (FGFR1) gene am...
Autores principales: | Fernanda Amary, M, Ye, Hongtao, Berisha, Fitim, Khatri, Bhavisha, Forbes, Georgina, Lehovsky, Katie, Frezza, Anna M, Behjati, Sam, Tarpey, Patrick, Pillay, Nischalan, Campbell, Peter J, Tirabosco, Roberto, Presneau, Nadège, Strauss, Sandra J, Flanagan, Adrienne M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303166/ https://www.ncbi.nlm.nih.gov/pubmed/24861215 http://dx.doi.org/10.1002/cam4.268 |
Ejemplares similares
-
Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics
por: Presneau, Nadège, et al.
Publicado: (2015) -
Clinical outcome in patients with peripherally‐sited atypical lipomatous tumours and dedifferentiated liposarcoma
por: Kalimuthu, Sangeetha N, et al.
Publicado: (2015) -
Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas
por: Presneau, Nadège, et al.
Publicado: (2017) -
Synovial chondromatosis and soft tissue chondroma: extra-osseous cartilaginous tumours defined by FN1 gene rearrangement
por: Amary, Fernanda, et al.
Publicado: (2019) -
H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone
por: Amary, Fernanda, et al.
Publicado: (2017)